Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merit Cudkowicz

Showing results (51-60 of 111) with videos related to

Pageof 12
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 24, 2015
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Neta Zach, David L Ennist, Albert A Taylor, et al.
Muscle & Nerve|April 23, 2015
Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosisSabrina Paganoni, Theodore Hyman, Amy Shui, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 11, 2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment TrialRichard Smith, Erik Pioro, Kathleen Myers, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2019
IL6 receptor<sup>358</sup>Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosisMarlena Wosiski-Kuhn, Mac Robinson, Jane Strupe, et al.
Muscle & Nerve|April 5, 2013
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosisJulien Cohen-Adad, Wei Zhao, Boris Keil, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2014
Seeking a measure of clinically meaningful change in ALSMartin McElhiney, Judith G Rabkin, Raymond Goetz, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 18, 2015
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALSRobert G Miller, Gilbert Block, Jonathan S Katz, et al.
BMC Neurology|May 31, 2019
Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALSAnne Marie Wills, Jamie Garry, Jane Hubbard, et al.
Annals of Clinical and Translational Neurology|June 22, 2018
Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALSStephen A Goutman, Morton B Brown, Jonathan D Glass, et al.
Pageof 12

Showing results (51-60 of 111) with videos related to

Sort By:
Pageof 12
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 24, 2015
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Neta Zach, David L Ennist, Albert A Taylor, et al.
Muscle & Nerve|April 23, 2015
Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosisSabrina Paganoni, Theodore Hyman, Amy Shui, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 11, 2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment TrialRichard Smith, Erik Pioro, Kathleen Myers, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2019
IL6 receptor<sup>358</sup>Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosisMarlena Wosiski-Kuhn, Mac Robinson, Jane Strupe, et al.
Muscle & Nerve|April 5, 2013
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosisJulien Cohen-Adad, Wei Zhao, Boris Keil, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2014
Seeking a measure of clinically meaningful change in ALSMartin McElhiney, Judith G Rabkin, Raymond Goetz, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 18, 2015
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALSRobert G Miller, Gilbert Block, Jonathan S Katz, et al.
BMC Neurology|May 31, 2019
Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALSAnne Marie Wills, Jamie Garry, Jane Hubbard, et al.
Annals of Clinical and Translational Neurology|June 22, 2018
Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALSStephen A Goutman, Morton B Brown, Jonathan D Glass, et al.
Pageof 12